Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Anistreplase MeSH Descriptor Data 2026


MeSH Heading
Anistreplase
Tree Number(s)
D08.811.277.656.300.760.635.075
D08.811.277.656.300.775.075
D08.811.277.656.959.350.635.075
D12.776.124.125.662.537.075
Unique ID
D016255
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D016255
Scope Note
An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
Entry Term(s)
APSAC
Anisoylated Plasminogen-Streptokinase Activator Complex
BRL-26921
Eminase
Iminase
Pharm Action
Fibrinolytic Agents
Registry Numbers
81669-57-0
0
CAS Type 1 Name
Anistreplase
Previous Indexing
Fibrinolytic Agents (1966-1990)
Plasminogen (1966-1990)
Streptokinase (1966-1990)
Public MeSH Note
91
History Note
91
Date Introduced
1991/01/01
Last Updated
2016/07/01
Anistreplase Preferred
Eminase Narrower
BRL-26921 Narrower
Iminase Narrower
page delivered in 0.144s